基因疗法显著减少难治性癫痫患者的发作次数
Epileptic seizures nearly vanish after people receive experimental gene therapy in their brains
一项早期临床试验中,三种难治性癫痫患者在接受基因疗法后,每月发作次数减少超过90%。该疗法通过病毒将基因送入大脑特定区域,使神经元对特定药物敏感,从而减少癫痫发作。但需关注长期使用抗精神病药物的副作用。
首次报道基因疗法显著减少难治性癫痫患者的发作次数,但需关注长期副作用。
- NEWS
- 04 November 2026
A clinical trial in three people tested a combination of gene-laden viruses and a drug.
By
-
Mariana Lenharo
-
Mariana Lenharo is a reporter for Nature in New York City.
-

A scan shows the brain of a man with epilepsy. A newly developed gene therapy targets locations in the brain that are the root of epileptic seizures. Credit: Allison Robbert/The Washington Post/Getty
Three people with epilepsy resistant to drug treatment saw the number of seizures they had per month fall by more than 90%, after gene-laden viruses were infused directly into their brains as part of an early-stage clinical trial1.
In each participant, the gene therapy was precisely targeted to a small patch of brain tissue that was the source of their seizures. The viruses carried a gene that makes neurons sensitive to a specific drug, which works like a dimmer switch for the therapy. By combining gene therapy with a drug — an approach known as chemogenetics — researchers can adjust a treatment’s potency, which is not possible with other types of gene therapy. The trial participants did not experience serious side effects.
Genetic therapies offer new hope against incurable brain diseases
The results were reported today in The New England Journal of Medicine by Yang Dai, a neurosurgeon at Xuanwu Hospital of Capital Medical University in Beijing, and his colleagues. “It’s exciting that there’s such a dramatic effect, and that they see very few side effects,” says Matthew Walker, a neurologist at University College London who was not associated with the study.
But he cautions that the study is small. He is also concerned about the long-term use of the drug that participants took after receiving the gene therapy. High doses of the drug, an anti-psychotic called clozapine, have been associated with cardiovascular problems and other negative effects. “In the future, hopefully there are going to be better drugs” for this form of treatment, says Walker, who is the co-founder of the start-up company Focalis Bio in Canterbury, UK, which is also developing gene therapies for epilepsy.
Direct to the brain
The three trial participants were adults with a common form of epilepsy caused by hippocampal sclerosis, a type of scarring in a region of the brain called the hippocampus. The participants had this scarring on only one side of the hippocampus. All three had been diagnosed with epilepsy 10–25 years earlier and had developed resistance to at least two anti-seizure drugs. They also had at least two seizure episodes per month, on average, over the three months before they enrolled in the trial.
The experimental treatment uses a virus called adeno-associated virus 9 to deliver a gene to neurons in the affected area. The gene was engineered to produce proteins specifically in excitatory cells — the ones that are involved in seizures.
Brain editing now ‘closer to reality’: the gene-altering tools tackling deadly disorders
The gene instructs neurons to produce a receptor that binds to clozapine. Clozapine acts like a switch and activates these receptors, reducing the activity of the targeted neurons, the authors say. That reduced activity helps to suppress the abnormal electrical activity that triggers seizures.
doi: https://doi.org/10.1038/d41586-026-03566-2
Related Articles
-
Huntington’s disease treated for the first time using gene therapy
-
Gene therapy’s comeback: how scientists are trying to make it safer
Subjects
Latest on:
-
Gene therapy that led to boy’s death had limited efficacy
News 27 OCT 26
-
Restoring hearing in people with a rare form of deafness
Spotlight 30 SEP 26
-
‘Epigenetic’ editing is here: gene-tagging technique banishes hepatitis B virus
News 21 SEP 26
来源:Nature 综合主刊 · nature.com


Gene therapy that led to boy’s death had limited efficacy